Genfit S.A. (GNFTY)
OTCMKTS · Delayed Price · Currency is USD
5.62
-0.18 (-3.12%)
Dec 16, 2025, 4:00 PM EST
Genfit Revenue
Genfit had revenue of 35.54M EUR in the half year ending June 30, 2025, with 135.16% growth. This brings the company's revenue in the last twelve months to 45.13M, down -43.93% year-over-year. In the year 2024, Genfit had annual revenue of 70.69M with 105.01% growth.
Revenue (ttm)
45.13M EUR
Revenue Growth
-43.93%
P/S Ratio
5.56
Revenue / Employee
250.69K EUR
Employees
180
Market Cap
294.62M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70.69M | 36.21M | 105.01% |
| Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
| Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
| Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
| Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |
Genfit News
- 7 days ago - GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy - GlobeNewsWire
- 20 days ago - GENFIT Announces Appointment of new Chief Medical Officer - GlobeNewsWire
- 27 days ago - GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update - GlobeNewsWire
- 27 days ago - GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market - GlobeNewsWire
- 5 weeks ago - GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF - GlobeNewsWire
- 5 weeks ago - GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025 - GlobeNewsWire
- 6 weeks ago - GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market - GlobeNewsWire
- 7 weeks ago - GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025 - GlobeNewsWire